Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.85 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.85 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | APEX1 | P27695 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | GHSR | Q92847 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CCR2 | P41597 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL337396 | 0.92 | ALDH1A1 (1.00) | ALDH1A1KDM4EL3MBTL1CHRNA7MAPT | |
| SCHEMBL337149 | 0.92 | ALDH1A1 (1.00) | ALDH1A1KDM4EL3MBTL1CHRNA7MAPT | |
| SCHEMBL7383705 | 0.90 | ALDH1A1 (0.75) | ALDH1A1KDM4EL3MBTL1TDP1GAA | |
| SCHEMBL11329761 | 0.88 | ALDH1A1 (0.72) | ALDH1A1KDM4EL3MBTL1MAPTTDP1 | |
| SCHEMBL13165143 | 0.87 | KDM4E (0.66) | ALDH1A1KDM4EL3MBTL1CHRNA7MAPT | |
| SCHEMBL2115680 | 0.86 | ALDH1A1 (0.89) | ALDH1A1KDM4EL3MBTL1TDP1MEN1 | |
| SCHEMBL16062994 | 0.84 | KDM4E (0.62) | ALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL25687896 | 0.84 | ALDH1A1 (0.85) | ALDH1A1KDM4EL3MBTL1MAPTTDP1 | |
| SCHEMBL25598757 | 0.84 | ALDH1A1 (0.85) | ALDH1A1KDM4EL3MBTL1MAPTTDP1 | |
| SCHEMBL2301305 | 0.83 | ALDH1A1 (0.71) | ALDH1A1KDM4EL3MBTL1MAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11583538-B2 | Substituted pyrrolo[1,2-a]pyrazines and pyrrolo[1,2-a][1,4]diazepines as TREX1 inhibitors | Venenum Biodesign, LLC (US) | 2023-02-21 | — | — | US | disclosed |
| US-20210015829-A1 | CYCLIC TREX1 INHIBITORS | Venenum Biodesign, LLC (US) | 2021-01-21 | — | — | US | disclosed |
| US-8097618-B2 | Pyridine derivatives and their use in the treatment of psychotic disorders | GLAXOSMITHKLINE LLC (US) | 2012-01-17 | — | — | US | disclosed |
| US-20110190276-A1 | Pyridine Derivatives And Their Use In The Treatment Of Psychotic Disorders | KaNDy Therapeutics Limited (GB) | 2011-08-04 | — | — | US | disclosed |
| EP-2336136-A1 | Pyridine derivatives and their use in the treatment of psychotic disorders | GlaxoSmithKline LLC (US) | 2011-06-22 | — | — | EP | disclosed |
| US-7919491-B2 | Pyridine derivatives and their use in the treatment of psychotic disorders | GLAXOSMITHKLINE LLC (US) | 2011-04-05 | — | — | US | disclosed |
| US-20100152175-A1 | Pyridine Derivatives and Their Use in The Treatment of Psychotic Disorders | GLAXOSMITHKLINE LLC (US) | 2010-06-17 | — | — | US | disclosed |
| US-7683056-B2 | Pyridine derivatives and their use in the treatment of psychotic disorders | GLAXOSMITHKLINE LLC (US) | 2010-03-23 | — | — | US | disclosed |
| US-20080269208-A1 | Pyridine Derivatives and Their Use in the Treatment of Psychotic Disorders | KaNDy Therapeutics Limited (GB) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190276-A1 | Pyridine Derivatives And Their Use In The Treatment Of Psychotic Disorders | NDUFB7, NDUFB6, GABRE | ALDH1A1 337/4885KDM4E 3462/4885L3MBTL1 3970/4885 |
| US-11583538-B2 | Substituted pyrrolo[1,2-a]pyrazines and pyrrolo[1,2-a][1,4]diazepines as TREX1 inhibitors | TMX1, P2RX1, TCOF1 | ALDH1A1 664/4885KDM4E 2540/4885L3MBTL1 3293/4885 |
| US-20210015829-A1 | CYCLIC TREX1 INHIBITORS | TMX1, TSNAX, TPX2 | ALDH1A1 1307/4885KDM4E 2466/4885L3MBTL1 1933/4885 |
| US-20080269208-A1 | Pyridine Derivatives and Their Use in the Treatment of Psychotic Disorders | SLC6A3, NDUFS5, NDUFB6 | ALDH1A1 490/4885KDM4E 1960/4885L3MBTL1 4767/4885 |
| US-20100152175-A1 | Pyridine Derivatives and Their Use in The Treatment of Psychotic Disorders | CHRNA7, NR3C2, CHRNA6 | ALDH1A1 1956/4885KDM4E 4100/4885L3MBTL1 2427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.